Massmutual Trust Co. FSB ADV Increases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Massmutual Trust Co. FSB ADV raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 24.7% during the first quarter, Holdings Channel.com reports. The firm owned 691 shares of the medical equipment provider’s stock after purchasing an additional 137 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Hologic were worth $54,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Victory Capital Management Inc. raised its position in Hologic by 4.5% in the fourth quarter. Victory Capital Management Inc. now owns 5,055,048 shares of the medical equipment provider’s stock valued at $361,183,000 after purchasing an additional 216,958 shares during the period. Norges Bank purchased a new stake in shares of Hologic in the 4th quarter valued at $217,529,000. The Manufacturers Life Insurance Company raised its holdings in shares of Hologic by 117.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after buying an additional 1,168,564 shares during the period. TD Asset Management Inc raised its holdings in shares of Hologic by 2.8% in the 4th quarter. TD Asset Management Inc now owns 1,897,705 shares of the medical equipment provider’s stock valued at $135,591,000 after buying an additional 52,243 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its holdings in shares of Hologic by 2.9% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 1,634,362 shares of the medical equipment provider’s stock valued at $115,586,000 after buying an additional 45,785 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.2 %

NASDAQ:HOLX opened at $73.07 on Friday. The stock has a 50-day simple moving average of $74.59 and a 200-day simple moving average of $74.17. The stock has a market cap of $17.05 billion, a P/E ratio of 37.28, a P/E/G ratio of 2.40 and a beta of 1.00. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $82.45. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same period in the prior year, the firm posted $1.06 EPS. The business’s quarterly revenue was down .8% compared to the same quarter last year. As a group, analysts anticipate that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on HOLX shares. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Argus boosted their target price on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. JPMorgan Chase & Co. boosted their target price on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Finally, Evercore ISI boosted their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $85.60.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.